dapirolizumab pegol
UCB and Biogen’s lupus drug falls short at Phase 2b
October 24, 2018Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
